75% ORR in maintenance therapy in multiple myeloma patients
- Patients with MM have a median survival of at least 10 years, and despite improvements in prognosis, almost all patients will eventually relapse
- Ixazomib is an oral proteasome inhibitor (PI) approved for patients who have received at least 1 previous therapy for MM
- A total of 71 patients with newly diagnosed MM were observed after response plateauing between April 2018 and April 2020. The overall response rate (ORR) was 81.7%, including 34 patients (47.9%) with a very good partial response rate or better (≥VGPR) after induction therapy. The ORR was transformed to 74.6% including 39 patients of ≥VGPR (54.9%) after maintenance therapy
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.